BR112015032637A2 - derivados de pirrolopiridina ou pirazolopiridina - Google Patents
derivados de pirrolopiridina ou pirazolopiridinaInfo
- Publication number
- BR112015032637A2 BR112015032637A2 BR112015032637A BR112015032637A BR112015032637A2 BR 112015032637 A2 BR112015032637 A2 BR 112015032637A2 BR 112015032637 A BR112015032637 A BR 112015032637A BR 112015032637 A BR112015032637 A BR 112015032637A BR 112015032637 A2 BR112015032637 A2 BR 112015032637A2
- Authority
- BR
- Brazil
- Prior art keywords
- lower alkyl
- hydroxy
- substituted
- optionally substituted
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
Abstract
a presente invenção refere-se a compostos de fórmula i em que r1 é halogênio, alquila inferior, alcóxi inferior, ciano, feni-la, c(o)nhch3, c(o)nh2, alquila inferior substituída por halogênio ou é um grupo heteroarila de cinco membros, opcionalmente substituído por alquila inferior; y1 é n ou ch; y2 é ch; e se y1 for ch, y1 e y2 podem formar, junto com os átomos de c aos quais eles estão ligados, um anel, contendo –ch=n-n(ch3)-, -ch=n-n(h)-; x é ch ou n; r é (ch2)m-cicloalquila, opcio-nalmente substituída por hidróxi, alcóxi inferior ou alquila inferior, ou é tetra-hidropirano, opcionalmente substituído por hidróxi ou é alcóxi inferior, substi-tuído por hidróxi, ou é alquila inferior substituída por um ou dois hidróxi, ou é (ch2)m-piridinila, opcionalmente substituída por hidróxi, alquila inferior ou alquila inferior substituída por hidróxi, ou é l-fenila, opcionalmente substituí-da por hidróxi, alquila inferior ou alquila inferior substituída por hidróxi, e l é uma ligação, -ch(ch2oh)- ou –ch2ch(oh)-; n é 0, 1 ou 2; m é 0 ou 1; ou a um sal de adição de ácido farmaceuticamente aceitável, a uma mistura ra-cêmica ou a seu enantiômero e/ou isômeros ópticos correspondentes destes. os compostos da presente invenção são moduladores alostéricos positi-vos (pam) de receptor muscarínico m1 e, então, são úteis no tratamento de doenças mediadas pelo receptor muscarínico m1 como, por exemplo, mal de alzheimer, disfunção cognitiva, esquizofrenia, dor ou desordens de sono.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13182351 | 2013-08-30 | ||
| PCT/EP2014/068114 WO2015028483A1 (en) | 2013-08-30 | 2014-08-27 | Pyrrolopyridine or pyrazolopyridine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015032637A2 true BR112015032637A2 (pt) | 2017-07-25 |
Family
ID=49036519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015032637A BR112015032637A2 (pt) | 2013-08-30 | 2014-08-27 | derivados de pirrolopiridina ou pirazolopiridina |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9932335B2 (pt) |
| EP (1) | EP3039024A1 (pt) |
| JP (1) | JP6434516B2 (pt) |
| KR (1) | KR20160035068A (pt) |
| CN (2) | CN105358559A (pt) |
| AR (1) | AR099640A1 (pt) |
| BR (1) | BR112015032637A2 (pt) |
| CA (1) | CA2915952A1 (pt) |
| HK (1) | HK1215575A1 (pt) |
| MX (1) | MX2015017343A (pt) |
| RU (1) | RU2016110483A (pt) |
| TW (1) | TW201512197A (pt) |
| WO (1) | WO2015028483A1 (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
| JP6517239B2 (ja) | 2014-04-23 | 2019-05-22 | 武田薬品工業株式会社 | アルツハイマー病治療のためのコリン作動性ムスカリンｍ１受容体ポジティブアロステリックモジュレーター活性としてのイソインドリン−１−オン誘導体 |
| WO2015174534A1 (ja) | 2014-05-16 | 2015-11-19 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| TR201904639T4 (tr) * | 2015-06-08 | 2019-05-21 | Suven Life Sciences Ltd | Muskarinik M1 reseptörü pozitif allosterik modülatörler. |
| MX2018002821A (es) | 2015-09-10 | 2018-09-12 | Suven Life Sciences Ltd | Derivados de fluoroindol como moduladores alostéricos positivos del receptor m1 muscarínico. |
| MX2018009952A (es) * | 2016-02-16 | 2018-11-29 | Univ Vanderbilt | Moduladores alostericos positivos del receptor de acetilcolina muscarinico m1. |
| RS60875B1 (sr) * | 2016-09-02 | 2020-11-30 | Suven Life Sciences Ltd | Pozitivni alosterni modulatori muskarinskog m1 receptora |
| WO2018063552A1 (en) | 2016-09-30 | 2018-04-05 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
| WO2019000236A1 (en) * | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| WO2019000238A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| WO2019000237A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| BR112020007606A2 (pt) * | 2017-10-18 | 2020-09-29 | Suven Life Sciences Limited | composto, composição farmacêutica, uso do composto e da composição farmacêutica e combinação |
| MX2020004339A (es) * | 2017-10-27 | 2020-08-03 | Suven Life Sciences Ltd | Moduladores alostericos positivos del receptor m1 muscarinico. |
| KR20210021042A (ko) * | 2018-06-15 | 2021-02-24 | 카딜라 핼쓰캐어 리미티드 | 포유동물 감염 치료를 위한 신규한 화합물 |
| US12065433B2 (en) | 2018-10-24 | 2024-08-20 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 |
| WO2023082044A1 (zh) * | 2021-11-09 | 2023-05-19 | 暨南大学 | 5-醛基杂环酰胺类化合物及其应用 |
| CN116102549A (zh) * | 2021-11-09 | 2023-05-12 | 暨南大学 | 5-醛基杂环酰胺类化合物及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5461067A (en) * | 1993-02-25 | 1995-10-24 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US8012992B2 (en) * | 2008-06-30 | 2011-09-06 | Allergan, Inc. | Aza-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity |
| WO2010019391A1 (en) * | 2008-08-12 | 2010-02-18 | Merck Sharp & Dohme Corp. | N-heterocyclic m1 receptor positive allosteric modulators |
| WO2011041143A1 (en) * | 2009-10-01 | 2011-04-07 | Merck Sharp & Dohme Corp. | HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS |
| HUE029734T2 (en) * | 2009-12-17 | 2017-03-28 | Merck Sharp & Dohme | Kinolin amide M1 receptor positive allosteric modulators |
| EP2575454B1 (en) * | 2010-05-28 | 2018-08-29 | Merck Sharp & Dohme Corp. | Naphthalene carboxamide m1 receptor positive allosteric modulators |
| WO2013106795A1 (en) * | 2012-01-12 | 2013-07-18 | Vanderbilt University | Substituted 4-(1h~pyrazol-4.yl)benzyl analogues as positive allosteric modulators of machr m1 receptors |
| ES2644025T3 (es) * | 2013-07-17 | 2017-11-27 | Global Alliance For Tb Drug Development | Compuestos de azaindol, síntesis de los mismos, y procedimientos de uso de los mismos |
-
2014
- 2014-08-26 TW TW103129408A patent/TW201512197A/zh unknown
- 2014-08-27 AR ARP140103205A patent/AR099640A1/es unknown
- 2014-08-27 KR KR1020167005141A patent/KR20160035068A/ko active IP Right Grant
- 2014-08-27 EP EP14755820.9A patent/EP3039024A1/en not_active Withdrawn
- 2014-08-27 RU RU2016110483A patent/RU2016110483A/ru unknown
- 2014-08-27 MX MX2015017343A patent/MX2015017343A/es unknown
- 2014-08-27 CN CN201480038043.7A patent/CN105358559A/zh active Pending
- 2014-08-27 BR BR112015032637A patent/BR112015032637A2/pt not_active Application Discontinuation
- 2014-08-27 WO PCT/EP2014/068114 patent/WO2015028483A1/en active Application Filing
- 2014-08-27 JP JP2016537274A patent/JP6434516B2/ja not_active Expired - Fee Related
- 2014-08-27 CA CA2915952A patent/CA2915952A1/en not_active Abandoned
- 2014-08-27 CN CN201810375657.4A patent/CN108558867A/zh active Pending
-
2016
- 2016-03-11 US US15/068,096 patent/US9932335B2/en active Active
- 2016-03-24 HK HK16103515.2A patent/HK1215575A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3039024A1 (en) | 2016-07-06 |
| MX2015017343A (es) | 2016-04-06 |
| RU2016110483A (ru) | 2017-10-04 |
| US9932335B2 (en) | 2018-04-03 |
| CN105358559A (zh) | 2016-02-24 |
| TW201512197A (zh) | 2015-04-01 |
| JP2016529268A (ja) | 2016-09-23 |
| US20160194321A1 (en) | 2016-07-07 |
| CN108558867A (zh) | 2018-09-21 |
| CA2915952A1 (en) | 2015-03-05 |
| WO2015028483A1 (en) | 2015-03-05 |
| JP6434516B2 (ja) | 2018-12-05 |
| HK1215575A1 (zh) | 2016-09-02 |
| KR20160035068A (ko) | 2016-03-30 |
| AR099640A1 (es) | 2016-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015032637A2 (pt) | derivados de pirrolopiridina ou pirazolopiridina | |
| MX2015015893A (es) | 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen. | |
| PH12015501878A1 (en) | Tetrahydroimidazo[1,5-d][1,4]oxazepine derivative | |
| PE20141553A1 (es) | Compuestos de triazolopiridina como inhibidores de la ped10a | |
| EA201391029A1 (ru) | Производные оксазина и их применение при лечении неврологических нарушений | |
| AR073314A1 (es) | Derivados de indazol o de 4,5,6,7-tetrahidro-indazol | |
| ATE517882T1 (de) | Chinolinderivate | |
| EA200970510A1 (ru) | Гетеромоноциклическое соединение и его применение | |
| EA201590453A1 (ru) | Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| NZ622072A (en) | Synthetic methods for spiro-oxindole compounds | |
| EA201200176A1 (ru) | Производные оксазина и их применение для лечения неврологических нарушений | |
| EA201001178A1 (ru) | 2-АЛКИЛАМИНО-3-АРИЛСУЛЬФОНИЛ-ЦИКЛОАЛКАНО[e ИЛИ d]ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТРЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
| EA201001683A1 (ru) | Производные фенил- или пиридинилзамещенных индазолов | |
| AR078756A1 (es) | Moduladores alostericos positivos (map) | |
| EA201300250A1 (ru) | Оксадиазольные ингибиторы продуцирования лейкотриена | |
| GB0507680D0 (en) | Compounds | |
| GEP20166483B (en) | Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament | |
| EA201370184A1 (ru) | Гетероарильные производные | |
| EA201200471A1 (ru) | Простые эфирные производные бициклических гетероарилов | |
| EA201100161A1 (ru) | Производные хинуклидина карбоната и их медицинские композиции | |
| CO6501188A2 (es) | Moduladores de piranil aril metil benzoquinazolina alostéricos positivos del receptos m1 | |
| SI2875011T1 (en) | 5-HT3 receptor antagonists | |
| EA201490630A1 (ru) | 6-замещенные 3-(хинолин-6-илтио)[1,2,4]триазоло[4,3-a]пиридины в качестве ингибиторов c-met тирозинкиназы | |
| MX2016008536A (es) | Derivados de fluoro-naftilo. | |
| AR085398A1 (es) | Ureas asimetricas y usos medicos de las mismas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |